login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Abbott launches MitraClip system in Australia


Friday, 15 Apr 2011 10:58
MitraClip
MitraClip


Abbott announced the launch of its catheter-based MitraClip system in Australia. The MitraClip device, which has received Therapeutic Goods Administration (TGA) approval, offers a new treatment option for patients suffering from mitral regurgitation.


This system includes a catheter-based device that is delivered to the heart through the femoral vein. It is designed to reduce significant mitral regurgitation by clipping together the leaflets of the mitral valve. Mitral regurgitation has traditionally been managed with medications, which can relieve symptoms but do not address the underlying cause of the condition, or open-heart surgery. According to Bach et al, many people who suffer from mitral regurgitation are not treated surgically because they are not referred to surgery, are not sick enough, or are too frail for an invasive procedure.

 

“The availability of the MitraClip system provides physicians with a safe, minimally invasive treatment for mitral regurgitation that may provide new hope for many people for whom surgery is not an option,” said Eric Yamen, Sir Charles Gairdner Hospital, Perth, Australia. “This therapy has the potential to improve the quality of life for many sick patients, enabling them to have a more active lifestyle.”

 

The first patients were successfully treated in Australia by interventional cardiologist, Eric Yamen; cardiothoracic surgeon, Jurgen Passage and echocardiologist, Christopher Finn; all from Sir Charles Gairdner Hospital, Perth, Australia.

 

Robert Hance, senior vice president, Vascular, Abbott, commented “Nearly 3,000 patients around the world have benefited from MitraClip treatment, and we are pleased that it is now commercially available in Australia.”

 

New clinical study to gather additional clinical and health-economic data

 

Abbott also announced the initiation of a new clinical study of the MitraClip device that will enroll up to 150 patients at up to 15 sites in Australia and New Zealand. The primary objective of the single-arm, prospective trial is to gather real-world clinical and health-economic outcome data to evaluate the long-term safety, efficacy and economic value of the MitraClip system. Patients in the study will be evaluated at discharge and after 30 days and six, 12 and 24 months following the procedure.

 

Patients will be selected for inclusion in the study by a multidisciplinary team involving specialists in interventional cardiology, cardiac surgery and echocardiology.

 

David Muller, director of the Cardiac Catheterization Laboratories, St Vincent’s Hospital, Sydney, Australia, and Jurgen Passage, cardiothoracic surgeon, Sir Charles Gairdner Hospital, Perth, Australia, will serve as the principal investigators of the study.

 

About the MitraClip technology and procedure

 

The catheter-based MitraClip device is delivered to the heart through the femoral vein. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. After treatment, patients are usually home within two to three days and have been observed to recover quickly. The safety and efficacy of the MitraClip system was evaluated in EVEREST II, the first randomised clinical trial to compare a catheter-based mitral valve device to mitral valve surgery.

 

The MitraClip system was CE marked in March 2008 and is commercially available in Europe, Turkey, Israel and Australia. The first-in-man clinical trial of the MitraClip system was conducted in the United States, where it is an investigational device currently under review for approval by the FDA.

 

 

 




Add New Comment

Related Items


Most popular


Bioresorbable scaffolds have the potential “to be workhorse stents”
Thursday, 07 May 2015
Last year, the GHOST-EU registry indicated that the rate of scaffold thrombosis with the bioresorbable vascular scaffold (Absorb, Abbott Vascular) was “not negilible”. However, as technological ... Bioresorbable scaffolds have the potential “to be workhorse stents”

Merit Medical Systems launches the Prelude Snap splittable sheath introducer
Wednesday, 03 Jun 2015
Merit Medical Systems has launched the Prelude Snap splittable sheath introducer, the design of which is based directly on physician feedback. Merit Medical Systems launches the Prelude Snap splittable sheath introducer

LowerMyDose website launches
Wednesday, 03 Jun 2015
LowerMyDose.com promotes peer-to-peer engagement through real-life experience sharing about the concerns of excessive and unnecessary radiation exposure. LowerMyDose website launches

Features


The importance of the PLATINUM DIVERSITY trial
Wednesday, 24 Jun 2015
The PLATINUM DIVERSITY trial was initiated last year with the aim of evaluating the clinical outcomes of an everolimus-eluting stent (Promus Premier, Boston Scientific) in patient populations that ... The importance of the PLATINUM DIVERSITY trial

The current status of transcatheter pulmonary valve replacement
Tuesday, 09 Jun 2015
The Melody transcatheter pulmonary valve (Medtronic), which received the CE mark in 2006 and FDA humanitarian device exemption approval in 2010, was recently granted FDA premarket approval. In this ... The current status of transcatheter pulmonary valve replacement

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions